

SUSTAINABILITY ACCOUNTING STANDARDS BOARD (SASB) INDEX

Fresenius Group compiles and discloses data based on the metrics of the Sustainability Accounting Standards Board (SASB) in its Index 2021. Going forward, we continuously strive to improve our disclosure of quantitative metrics and further enhance our SASB reporting. With this process, we are acknowledging the growing importance of the SASB standard among our investors.

Our disclosures are based on the Sustainable Industry Classification System (SICS) industries within the health industry sector, with a focus on those sectors that best reflect our different business fields: Biotechnology & Pharmaceuticals (BP), Health Care Delivery (DY), Health Care Distributors (DI), and Medical Equipment & Supplies (MS). Due to the diversified business model of Fresenius SE & Co. KGaA and its subsidiaries, only those indicators of the identified industry standards which are relevant for our operations are included in the index provided.

The majority of references within this index refer to the Fresenius 2021 Group Annual Report (see: <https://annualreport.fresenius.com/2021>), including the Fresenius 2021 Separate Group Non-financial Report (see pages 113 ff. of the Group Annual Report 2021), as well as the Fresenius 2021 Sustainability Report (see: <https://annualreport.fresenius.com/2021/sustainability-report/>), and the 2021 SASB Index of our business segment Fresenius Medical Care (see: <https://www.freseniusmedicalcare.com/en/sasb>).

Unless otherwise stated, all reported data are as of December 31, 2021.

Topic	Code	Accounting metric	Comment and Link
Biotechnology & Pharmaceuticals			
Safety of Clinical Trial Participants	HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	<p>Fresenius Group reports on the management approach with regard to clinical trials and clinical study management as well as on its organization and relevant guidelines or policies. Information is provided for all business segments with a focus on clinical study management in our hospitals. It is ensured that scientific, ethical and legal requirements are met. Only studies with an existing ethical vote and in compliance with all patients' rights are carried out. Detailed information is provided to a patient who decides to participate in a study by specially trained and dedicated staff. Patients are free to decide whether or not to participate.</p> <p>Fresenius Separate Group Non-financial Report 2021 -Section Digital Transformation and Innovation > Clinical research and innovative treatment management (p. 142 ff.) > Clinical research and innovative treatment management > Fresenius Medical Care (p. 142 f.) > Clinical research and innovative treatment management > Fresenius Kabi (p. 143) > Clinical research and innovative treatment management > Fresenius Helios (p. 143 f.) > Clinical research and innovative treatment management > Fresenius Vamed (p. 145)</p> <p>Fresenius Sustainability Online Report 2021: https://annualreport.fresenius.com/2021/sustainability-report/</p> <p>Fresenius Medical Care 2021 Annual Medical Report, available at: https://www.freseniusmedicalcare.com/en/about-us/sustainability/medical-responsibility</p> <p>Caring for Human Rights - https://www.fresenius.com/human-rights</p>
	HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	<p>Fresenius Group reports on the management approach with regard to clinical trials and clinical study management as well as on its organization and relevant guidelines or policies. Information is provided for all business segments with a focus on clinical study management in our hospitals. It is ensured that scientific, ethical and legal requirements are met. Only studies with an existing ethical vote and in compliance with all patients' rights are carried out. Detailed information is provided to a patient who decides to participate in a study by specially trained and dedicated staff. Patients are free to decide whether or not to participate. Inspections conducted by external bodies are not published separately. At Fresenius Kabi, the total number of inspections in the reporting year is provided.</p> <p>Fresenius Separate Group Non-financial Report 2021: Patient and product safety > Fresenius Kabi > Evaluation > Audits and inspections (p. 135) Digital Transformation and Innovation > Clinical research and innovative treatment management (p. 142 ff.)</p>

	HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	All relevant legal proceedings and related financial affects are disclosed in our Fresenius Group Annual Report 2021 - Note 30: Commitments and contingencies (p. 342 ff.)
Access to Medicines	HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Fresenius Separate Group Non-financial Report 2021 > Access to health care and medicine (p. 121 ff.) > Health care delivery during the COVID-19 pandemic (p. 125 ff.)
	HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Fresenius has one product on the WHO List of Prequalified Medicinal Products as of the reporting year 2021: Fresenius Kabi is listed as diluent supplier for BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – COMIRNATY® See WHO - Prequalification of Medical Products: https://extranet.who.int/pqweb/search?search_api_views_fulltext=Fresenius
Drug Safety	HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	MedWatch: The FDA Safety Information and Adverse Event Reporting Program: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
	HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	FDA Adverse Event Reporting System (FAERS) Public Dashboard: https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/analysis
	HC-BP-250a.3	Number of recalls issued, total units recalled	Fresenius Group does not report on the numbers of recalls or total units recalled, currently. It is our aim to act fast and proactively concerning recall execution in order to minimize potential risks for patients. The recalls are discussed and agreed on beforehand with the respective authority. For information on our approach towards recalls, see: Fresenius Separate Group Non-financial Report 2021 - Well being of the patient > Patient and product safety > Fresenius Medical Care > Handling product complaints (p. 132) > Patient and product safety > Fresenius Kabi > Product risk management (p. 133)
	HC-BP-250a.5/ HC-MS-250a.4	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	We report on inspections and enforcement actions taken, if material for the operating business, in our quarterly and annual reports. Fresenius Group Annual Report 2021 - Risk Management (p. 95 ff) Fresenius Group Non-financial Report 2021 - Well being of the patient > Patient and product safety > Fresenius Medical Care > Evaluation > Audits (p. 132) > Fresenius Kabi > Evaluation > Audits and inspections (p. 135)
Counterfeit Drugs	HC-BP-260a.1/ HC-DI-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	Fresenius Medical Care: https://fmcna.com/company/corporate-responsibility/compliance/ Fresenius Kabi: Fresenius Separate Group Non-financial Report 2021: > Well being of the patient > Patient and product safety > Fresenius Kabi > Labeling and product information (p. 133 f.) > Digital Transformation and Innovation > Digitalization and innovation in the business segments > Fresenius Kabi > Progress and measures in 2021 (p. 146) Fresenius Kabi Drug Supply Chain Security Act (DSCSA): https://www.fresenius-kabi.com/us/drug-supply-chain-security-act-dcsa
Ethical Marketing	HC-BP-270a.1/ HC-MS-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2021 Group Annual Report - Note 30: Commitments and contingencies (p. 342 ff.)

	HC-BP-270a.2/ HC-MS-270a.2	Description of code of ethics governing promotion of off-label use of products	<p>Fresenius Medical Care: https://www.freseniusmedicalcare.com/fileadmin/data/com/pdf/About_us/Compliance/CoC/FME_CoC_English.pdf</p> <p>Fresenius Kabi: https://www.fresenius-kabi.com/us/documents/Code-of-Conduct-Fresenius-Kabi-USA.pdf</p> <p>Fresenius Separate Group Non-financial Report 2021 - Well being of the patient > Patient and product safety > Fresenius Kabi > Labeling and product information (p. 133 f.)</p>
Employee Recruitment, Development & Retention	HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	<p>Only 1% of the Group employees are engaged in Research and Development, because we do not conduct basic research. Thus, there are no additional efforts to recruit or retent scientist and research development personnel. For overarching measures, please see:</p> <p>Fresenius 2021 Group Management Report - Research and Development (p. 51)</p> <p>Fresenius Separate Group Non-financial Report 2021 - Employees > Working conditions, recruitment, and employee participation (p. 154 ff.) > Employee development (p. 165 ff.)</p>
	HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	<p>Fresenius discloses the voluntary turnover for each business segment and for the Group per region, but not as a break-down for management levels. We aim to improve the reporting scope on recruitment data going forward and assess internally to add further KPIs for this aspect.</p> <p>Fresenius Separate Group Non-financial Report 2021 > Employees > Working conditions, recruitment, and employee participation > Evaluation (p. 162 ff.)</p> <p>Voluntary turnover by region (reporting started in 2021): https://annualreport.fresenius.com/2021/sustainability-report/employees/working-conditions-recruitment-and-employee-participation/</p>
Supply Chain Management	HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent thirdparty audit programs for integrity of supply chain and ingredients	<p>Fresenius Group aims to further improve the reporting and transparency provided on supply chain management in the Fresenius Group Non-financial report, i.e. if there are audit programs of relevance for Fresenius Group.</p> <p>Fresenius Separate Group Non-financial Report 2021: Supply Chain > Progress and measures 2021 > Supplier evaluation (p. 197 ff.)</p>
Business Ethics	HC-BP-510a.1/ HC-DI-510a.2/ HC-MS-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	<p>All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2021 Group Annual Report - Note 30: Commitments and contingencies (p. 342 ff.)</p>
	HC-BP-510a.2/ HC-MS-510a.2	Description of code of ethics governing interactions with health care professionals	<p>Fresenius Separate Group Non-financial Report 2021 - Compliance and integrity > Compliance > Guidelines and regulations (p.183ff.) Fresenius Group Compliance: https://www.fresenius.com/compliance</p> <p>Fresenius Medical Care: see the business segments' website: www.freseniusmedicalcare.com https://www.freseniusmedicalcare.com/en/about-us/compliance/compliance-overview https://www.freseniusmedicalcare.com/fileadmin/data/com/pdf/About_us/Compliance/CoC/FME_CoC_English.pdf</p> <p>Fresenius Kabi: see the business segments' website: www.fresenius-kabi.com https://www.fresenius-kabi.com/responsibilities/compliance https://www.fresenius-kabi.com/us/documents/Code-of-Conduct-Fresenius-Kabi-USA.pdf</p> <p>Fresenius Vamed: https://www.vamed.com/en/company/compliance</p>

Activity metrics	HC-BP-000.A	Number of patients treated	<p>Fresenius Helios discloses the number of patients treated in hospitals and as outpatients. Fresenius Group Annual Report 2021 - Business segments > Fresenius Helios (p. 14)</p> <p>Fresenius Medical Care treats more than 345,000 patients in its various dialysis clinics. Fresenius Group Management Report 2021 - Fundamental information about the Group > The Group's business model (p. 38)</p>
	HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	<p>We report in our biosimilar product segment on the clinical trials performed on product candidates: Fresenius 2021 Group Management Report - Research and Development > Fresenius Kabi (p. 53 f.)</p> <p>For our healthcare product portfolio please see: Fresenius 2021 Group Management Report - Research and Development (p. 51 ff.)</p>
Health Care Delivery			
Energy Management	HC-DY-130a.1	(1) Total energy consumed, (2) percentage grid electricity, (3) percentage renewable	<p>Fresenius Separate Group Non-financial Report 2021: Environment > Climate protection - energy and emissions > Evaluation (p. 213 ff.)</p> <p>(1) Conversion: Fresenius Group reports the total energy consumption in MWh. Converted into GJ, Fresenius Group consumed 21,011,815.11 GJ in 2021 (5.8 million MWh). (2) 37% (3) 2% of total energy consumption</p> <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p>
Waste Management	HC-DY-150a.1	Total amount of medical waste, percentage (a) incinerated, (b) recycled or treated, and (c) landfilled	<p>Fresenius Group aims to improve the reporting scope on waste management going forward. In 2021, we started providing information on hazardous and non-hazardous waste (Fresenius Helios) in relation to hospital beds in our Sustainability online report. We further provide the share of hazardous and non-hazardous waste in our German acute care hospitals.</p> <p>Fresenius Separate Group Non-financial Report 2021 - Environment > Waste and recycling management (p. 208 ff.) https://annualreport.fresenius.com/2021/sustainability-report/environment/waste-and-recycling-management/</p>
	HC-DY-150a.2	Total amount of: (1) hazardous and (2) nonhazardous pharmaceutical waste, percentage (a) incinerated, (b) recycled or treated, and (c) landfilled	<p>Fresenius Group aims to improve the reporting scope on waste management going forward. In 2021, we started providing quantitative information on hazardous and non-hazardous waste for Fresenius Kabi and Fresenius Helios. For Fresenius Helios we report also waste in relation to hospital beds in our Sustainability online report.</p> <p>Fresenius Separate Group Non-financial Report 2021 - Environment > Waste and recycling management (p. 208 ff.) https://annualreport.fresenius.com/2021/sustainability-report/environment/waste-and-recycling-management/</p>
Patient Privacy & Electronic Health Records	HC-DY-230a.1	Percentage of patient records that are Electronic Health Records (EHR) that meet "meaningful use" requirements	<p>Fresenius Helios started introducing a patient portal at its clinics in 2019. Patients can now access treatment documents such as diagnoses, book appointments online, or attend video consultations at 50 German clinics, around the clock and from home. The portal can be accessed via the websites of the respective clinics. In 2021, the patient portal recorded 130,000 registered users, 300,000 documents exchanged via the portal and nearly 85,000 online appointments.</p> <p>A digital patient file (electronic patient file - EPF) with doctor's letters, findings, and complete clinical imaging is available at the majority of workstations in the clinics. By 2022, other medical data such as nursing documentation and medication will also be available in the digital patient file at Fresenius Helios. Portal and EPFs are not listed in the Certified Health IT Product List as all applicable locations are based in Germany.</p> <p>Fresenius Group Non-financial Report 2021 - Digital transformation and innovation > Digitalization and innovation (p. 147f.)</p>
	HC-DY-230a.2	Description of policies and practices to secure customers' protected health information (PHI) records and other personally identifiable information (PII)	<p>Fresenius Separate Group Non-financial Report 2021: Compliance and Integrity > Compliance > Transparency in the health care sector (p. 185 f.) Compliance and Integrity > Data protection (p. 188 ff.)</p> <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p>

HC-DY-230a.3	(1) Number of data breaches, (2) percentage involving (a) personally identifiable information (PII) only and (b) protected health information (PHI), (3) number of customers affected in each category, (a) PII only and (b) PHI2	<p>In 2021, Fresenius received 659 reports on data protection via compliance reporting channels. However, we do not publish the total number of data breaches.</p> <p>Fresenius Separate Group Non-financial Report 2021: Compliance and Integrity > Compliance> Evaluation > Reports in 2021 (p. 187f.)</p> <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p>	
HC-DY-230a.4	Total amount of monetary losses as a result of legal proceedings associated with data security and privacy	<p>All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2021 Group Annual Report - Note 30: Commitments and contingencies (p. 342 ff.)</p> <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p>	
Access for Low-Income Patients	HC-DY-240a.2	<p>Amount of Medicare Disproportionate Share Hospital (DSH) adjustment payments received</p> <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p>	<p>Fresenius 2021 Group Annual Report - Risk Management > Risks in health care sector > Financing of health care and reimbursement systems (p. 101 f.)</p>
Quality of Care & Patient Satisfaction	HC-DY-250a.1	Average Hospital Value-Based Purchasing Total Performance Score and domain score, across all facilities	<p>We do not operate hospitals in the United States, only dialysis clinics. Consequently, this indicator is not relevant for us. General information on patient satisfaction can be found in the Fresenius Separate Group Non-financial Report 2021, section Well-being of the patient, see: Fresenius Medical Care > Patient satisfaction (p. 131) Fresenius Helios > Patient satisfaction measurement and grievance processes (p. 138) Fresenius Vamed > Measurement of patient satisfaction and grievance processes (p. 140 f.)</p> <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p>
HC-DY-250a.2	Number of Serious Reportable Events (SREs) as defined by the National Quality Forum (NQF)	<p>Fresenius Group reports on serious reportable events with regard to treatments in hospitals and health care facilities. The definition of Serious Reportable Events (SREs) as defined by the U.S. National Quality Forum (NQF) is comparable to those defined by the regulatory provisions, for example, in Germany, Spain and Latin America, where our business segments Fresenius Helios and Fresenius Vamed operate hospitals or health care facilities. We provide information both on serious events as well as critical incidents in our Fresenius Group Non-financial Report 2021 and our Sustainability Online Report.</p> <p>Fresenius Helios: Fresenius Group Non-financial Report 2021 - Well being of the patient > Patient and product safety > Fresenius Helios > Evaluation (p. 138) https://annualreport.fresenius.com/2021/sustainability-report/well-being-of-the-patient/patient-and-product-safety/</p>	
HC-DY-250a.3	Hospital-Acquired Condition (HAC) Score per hospital	<p>The U.S. Hospital-Acquired Condition (HAC) Score is not calculated for hospitals and health care facilities in the business segments Fresenius Helios and Fresenius Vamed. However, we report on indicators in our hospitals and health care facilities which are comparable to those of the HAC Score, such as MRSA infections. Overall, our evaluation of quality of care focuses on those indicators applicable to the respective reimbursement scheme of the countries we operate:</p> <p>Fresenius Separate Group Non-financial Report 2021 - Well being of the patient > Patient and product safety > Fresenius Medical Care > Evaluation (p. 131 f.) > Fresenius Kabi > Evaluation (p. 134 f.) > Fresenius Helios > Hygiene management in hospitals (p. 136) > Fresenius Helios > Evaluation (p. 137 ff.) > Fresenius Vamed > Hygiene management in rehabilitation and nursing care (p. 140) > Fresenius Vamed > Evaluation (p. 140 f.)</p>	

HC-DY-250a.4	Excess readmission ratio per hospital	<p>The 2010 Affordable Care Act (ACA) in the United States requires the U.S. Department of Health and Human Services (DHHS) to establish a Hospital Readmissions Reduction Program (RRP) to reduce Inpatient Prospective Payment System (IPPS) payments to hospitals for excess readmissions. (Source: https://www.hqinstitute.org/post/readmission-reduction-program) This U.S. specific regulation does not apply to hospitals subject to other regulatory reimbursement schemes, for example, in Germany. Therefore, we do not report this indicator for our acute care hospitals in Germany, Spain or Latin America.</p> <p>Information on our relevant hospitals markets and reimbursement are provided in our Annual Report 2021: Fresenius 2021 Group Management Report - Economic Report > Health care industry (p. 59 ff.)</p> <p>Information on our programs on quality of care are provided for each business segment: Fresenius Group Separate Non-financial Report 2021 - Well being of the patient > Patient and product safety (p. 127 ff.)</p>	
Management of Controlled Substances	HC-DY-260a.1	Description of policies and practices to manage the number of prescriptions issued for controlled substances	<p>At Fresenius Helios, we implemented measures to make antibiotic use transparent and safe. This is of high importance, because if for instance an antibiotic is administered in insufficient doses or for too long, a resistance can develop. This makes it all the more important to provide medical staff with comprehensive training and to take all safety precautions that contribute to successful treatment. Helios Germany is establishing a comprehensive training programme for its doctors to combat multi-resistant pathogens: since 2019, doctors are trained as antibiotic stewardship (ABS) specialists for each bed-managing department of our hospitals. In the coming years, a total of more than 600 doctors will be trained at Helios. The trained antibiotics advisors will then be able to advise their colleagues on the prescription of antibiotics. Another aim of the measures is to review the use of antibiotics in the clinics. Anomalies in consumption are recorded in targeted reviews. In this way, developments can be closely observed and analysed.</p> <p>Fresenius Separate Group Non-financial Report 2021 - Well being of the patient > Patient and product safety > Fresenius Helios > Hygiene management in hospitals (p. 136)</p> <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p> <p>List of antibiotics and amount per antibiotic used in treatments overall and per clinic in Germany of Fresenius Helios - https://www.helios-gesundheit.de/qualitaet/antibiotika/ (available in German language only)</p>
Employee Health & Safety	HC-DY-320a.1	(1) Total recordable incident rate (TRIR) and (2) days away, restricted, or transferred (DART) rate	<p>We disclose the lost time injury frequency rate (LTIRF) for Fresenius Kabi. It was 2.4 in 2021, an increase from 2.3 in 2020. Fresenius Helios is planning to implement the LTIFR in future.</p> <p>Fresenius Separate Group Non-financial Report 2021 - Employees > Occupational health and safety</p> <ul style="list-style-type: none"> > Our ambitions (p. 172) > Fresenius Kabi > Evaluation (p. 174) > Fresenius Helios > Evaluation (p. 176) <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p>
Employee Recruitment, Development & Retention	HC-DY-330a.1	(1) Voluntary and (2) involuntary turnover rate for: (a) physicians, (b) non-physician health care practitioners, and (c) all other employees	<p>We do not provide a split for physicians, non-physician health care practitioners but only for all employees in a business segment. However, the majority of employees are nurses and medical staff.</p> <p>Fresenius Group Non-financial Report 2021 - Employees > Working conditions, recruitment, and employee participation > Evaluation (pages 162 ff.)</p> <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p>
	HC-DY-330a.2	Description of talent recruitment and retention efforts for health care practitioners	<p>Fresenius Separate Group Non-financial Report 2021 - Employees</p> <ul style="list-style-type: none"> > Working conditions, recruitment, and employee participation > Employee retention (page 154) > Working conditions, recruitment, and employee participation (pages 156 ff.) > Employee development > Fresenius Helios (pages 166 ff.) <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p>

Climate Change Impacts on Human Health & Infrastructure	HC-DY-450a.1	Description of policies and practices to address: (1) the physical risks due to an increased frequency and intensity of extreme weather events and (2) changes in the morbidity and mortality rates of illnesses and diseases, associated with climate change	<p>Fresenius Group is currently assessing the impacts of climate change on our operating business. During the last reporting year, we started evaluating the impact of Scope 3 emissions. We will provide updates on these assessments in our non-financial reporting going forward.</p> <p>Fresenius Separate Group Non-financial Report 2021 > Strategy and management > Sustainability risks (p. 116) > Strategy and management > Our sustainability goals and programs (p. 117) > Strategy and management > EU-Taxonomy (p. 120) > Wellbeing of the patient > Access to health care and medicine > Patient support in crisis and emergency situations (p. 124 f.) > Environment > Our ambitions (p. 203)</p> <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p>
Fraud & Unnecessary Procedures	HC-DY-510a.1	Total amount of monetary losses as a result of legal proceedings associated with Medicare and Medicaid fraud under the False Claims Act	<p>All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2021 Group Annual Report - Note 30: Commitments and contingencies (p. 342 ff.)</p> <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p>
Activity metrics	HC-DY-000.A	Number of (1) facilities and (2) beds, by type	<p>Fresenius Medical Care: - 4,171 dialysis clinics in about 50 countries Fresenius Germany: - 90 clinics, 130 outpatient clinics, and 6 prevention centers - 29,955 acute care beds in Germany Fresenius Spain: - 45 hospitals, 88 outpatient centers and some 300 Occupational Risk Centers - 8,174 beds</p> <p>Fresenius Group Annual Report 2021 - Business segments > Fresenius Helios (p. 14) Fresenius Group Management Report 2021 - Economic Report > Health care industry (p. 59 ff.) Fresenius Group Fields of work - https://www.fresenius.com/hospitals</p>
	HC-DY-000.B	Number of (1) inpatient admissions and (2) outpatient visits	Fresenius Group Annual Report 2021 - Business segments > Fresenius Helios (p. 14): Table "Key hospital indicators"
Health Care Distributors			
Product Safety	HC-DI-250a.1	Total amount of monetary losses as a result of legal proceedings associated with product safety	All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2021 Group Annual Report - Note 30: Commitments and contingencies (p. 342 ff.)
	HC-DI-250a.2	Description of efforts to minimize health and safety risks of products sold associated with toxicity/chemical safety, high abuse potential, or delivery	Fresenius Group Annual Report 2021 - Risk Management (p. 95 ff) Fresenius Separate Group Non-financial Report 2021 - Well being of the patient > Patient and product safety (p. 127 ff.)
	HC-DI-260a.2	Discussion of due diligence process to qualify suppliers of drug products and medical equipment and devices	Suppliers related to product manufacturing are subject to qualification processes based on the relevance of the delivered material or service. At Fresenius Kabi the supplier's qualification and their recertification is regularly audited. <p>Fresenius Separate Group Non-financial Report 2021: - Well being of the patient > Patient and product safety > Fresenius Kabi > Evaluation > Audits and inspections (p. 135) - Compliance and Integrity > Supply Chain (p. 197 ff.)</p>
	HC-DI-260a.3	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	Fresenius Separate Group Non-financial Report 2021 - Well being of the patient > Patient and product safety > Fresenius Medical Care > Handling product complaints (p. 132) > Fresenius Kabi > Product risk management (p. 133) <p><i>Example: Fresenius Kabi - Pharmaceutical Products - https://www.fresenius-kabi.com/us/pharmaceutical-products</i></p>

Product Lifecycle Management	HC-DI-410a.1	Discussion of strategies to reduce the environmental impact of packaging throughout its lifecycle	<p>Fresenius Group aims to improve the reporting scope on waste management going forward. In 2021, we started to report on waste volumes in two business segments with indicators on hospital waste per bed.</p> <p>Fresenius Separate Group Non-financial Report 2021 - Environment > Waste and Recycling Management (p. 208 ff.) Waste volumes: https://annualreport.fresenius.com/2021/sustainability-report/environment/waste-and-recycling-management/</p>
Business Ethics	HC-DI-510a.1	Description of efforts to minimize conflicts of interest and unethical business practices	<p>Fresenius Separate Group Non-financial Report 2021 > Compliance and integrity (p. 182 ff.) Fresenius Separate Group Annual Report 2021 - Notes > Independence and conflicts of interest (p. 224)</p>
	HC-DI-510a.2	Total amount of monetary losses as a result of legal proceedings associated with bribery, corruption, or other unethical business practices	<p>All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2021 Group Annual Report - Note 30: Commitments and contingencies (p. 342 ff.)</p>
Activity metrics	HC-DI-000.A	Number of pharmaceutical units sold by product category	<p>We do not disclose the number of pharmaceutical units sold by product category, only sales by product segment. Fresenius 2021 Annual report - Business segments (p. 7 ff.)</p>
	HC-DI-000.B	Number of medical devices sold by product category	<p>We do not disclose the number of pharmaceutical units sold by product category, only sales by product segment. Fresenius 2021 Annual report - Business segments (p. 7 ff.)</p>
Medical Equipment & Supplies			
Product Safety	HC-MS-250a.1	Number of recalls issued, total units recalled	<p>Fresenius Group does not report on the total numbers of recalls or total units recalled. It is our aim to act fast and proactively concerning recall execution in order to minimize potential risks for patients. The recalls are discussed and agreed on beforehand with the respective authority.</p> <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p> <p>Fresenius Separate Group Non-financial Report 2021 - Well being of the patient > Patient and product safety > Fresenius Medical Care > Handling product complaints (p. 132) > Fresenius Kabi > Product risk management (p. 133)</p> <p><i>Example: Fresenius Kabi - Pharmaceutical Products</i> https://www.fresenius-kabi.com/us/pharmaceutical-products https://www.fresenius-kabi.com/us/pharmaceutical-product-updates</p> <p><i>See: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts?search_api_fulltext=Fresenius&field_regulated_product_field=All</i></p>
	HC-MS-250a.2	List of products listed in the FDA's MedWatch Safety Alerts for Human Medical Products database	<p>FDA Adverse Event Reporting: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program</p> <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p>
	HC-MS-250a.4	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by typ	<p>In the reporting year, there were no actions taken that stand against our quality goals. Fresenius Medical Care conducts quality audits and reviews on a regular basis. Guidelines of current Good Manufacturing Practice (cGMP) guidelines are taken into account, see:</p> <p>Fresenius Separate Group Non-financial Report 2021 - Well-being of the patient > Patient and product safety > Certifications and commitment (p. 129)</p> <p>SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb</p>

Ethical Marketing	HC-MS-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2021 Group Annual Report - Note 30: Commitments and contingencies (p. 342 ff.) SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb
Ethical Marketing	HC-MS-270a.2	Description of code of ethics governing promotion of off-label use of products	We provide information in the codes of ethics and conduct of our business segments governing promotion of off-label use of products, if applicable. <i>Examples:</i> <i>Fresenius Kabi USA: https://www.fresenius-kabi.com/us/documents/Code-of-Conduct-Fresenius-Kabi-USA.pdf</i> SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb Fresenius Medical Care Code of Ethics and Business Conduct: https://www.freseniusmedicalcare.com/fileadmin/data/com/pdf/About_us/Compliance/CoC/FME_CoC_English.pdf
Product Design & Lifecycle Management	HC-MS-410a.1	Discussion of process to assess and manage environmental and human health considerations associated with chemicals in products, and meet demand for sustainable products	Fresenius Medical Care conducts life cycle assessments for selected products and services to identify and improve environmental impacts of processes and materials. Fresenius Separate Group Non-financial Report 2021 - Environment > Environmental management in the business segments > Fresenius Medical Care > Life cycle assessments (p. 201) SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb
Supply Chain Management	HC-MS-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in third-party audit programs for manufacturing and product quality	Fresenius Group aims to improve the reporting scope on supply chain going forward. Fresenius Group Non-financial Report 2021 - Compliance and Integrity > Supply chain > Supplier evaluation (p. 197 ff.) SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb
	HC-MS-430a.2	Description of efforts to maintain traceability within the distribution chain	Fresenius Medical Care: https://www.freseniusmedicalcare.com/en/medical-device-regulation/ SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb Fresenius Kabi - Drug supply chain security act - https://www.fresenius-kabi.com/us/drug-supply-chain-security-act-dscsa
	HC-MS-430a.3	Description of the management of risks associated with the use of critical materials	Before the EU Conflict Minerals Regulation came into force, Fresenius SE & Co. KGaA and its operating units already addressed this sensitive issue. We do not purchase conflict minerals directly. However, it cannot be completely ruled out that they have been processed in components and semifinished products that we purchase and further process or use in our products. In this case, our purchasing guidelines apply, as do the relevant Group and business segment codes of conduct for dealing with suppliers and other business partners. https://annualreport.fresenius.com/2021/sustainability-report/compliance-and-integrity/human-rights/ SASB Index Fresenius Medical Care 2021: https://www.freseniusmedicalcare.com/en/sasb
Activity metrics	HC-MS-000.A	Number of units sold by product category	We do not disclose the number of products sold by category, only sales by product segment. Fresenius 2021 Group Annual report - Business segments - Fresenius Kabi (p. 10)